Astex Eyes First Filing For Oral Decitabine On Positive Combo Results

 
• By Ian Haydock

Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
Oral Decitabine Brings Dosing Convenience • Source: Shutterstock

More from Anticancer

More from Therapy Areas